Literature DB >> 6754845

Pre-exposure prophylaxis with immune serum globulin for prevention of viral hepatitis in army recruits.

J D Kark.   

Abstract

A controlled trial with pre-exposure immune serum globulin was undertaken in Israel Defence Forces (IDF) recruits, an indigenous population living in a hyperendemic area for hepatitis A. The objective was to examine whether the prevailing IDF policy of postexposure administration of immune serum globulin prophylaxis should be modified to further reduce the incidence of infectious hepatitis in the IDF. Altogether 23 447 recruits were systematically allocated on their first day of service into an intervention group and a control group. Over the 18-month follow-up period 18 cases of non-B viral hepatitis were identified among the 10 943 vaccinees and 41 among the 12 504 non-immunised group. Protection over six months was about 85%, and over the entire 18 months 50%. Protection was evident until about 40 weeks' follow-up and may have persisted for longer. Rates in the non-immunised were lower than expected, alluding to the possibility of herd immunity. IDF immunisation policy was successfully altered after this trial.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6754845      PMCID: PMC1052206          DOI: 10.1136/jech.36.3.176

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


  11 in total

1.  GAMMA-GLOBULIN IN THE PREVENTION ON VIRAL HEPATITIS: A STUDY OF THE EFFECT OF MEDIUM-SIZE DOSES.

Authors:  T KLUGE
Journal:  Acta Med Scand       Date:  1963-10

2.  Infectious hepatitis. Studies on the effect of gamma globulin and on the incidence of inapparent infection.

Authors:  S KRUGMAN; R WARD; J P GILES; A M JACOBS
Journal:  JAMA       Date:  1960-10-15       Impact factor: 56.272

3.  Gamma globulin in epidemic hepatitis: comparative value of two dosage levels, apparently near the minimal effective level.

Authors:  M E DRAKE; C MING
Journal:  J Am Med Assoc       Date:  1954-08-07

4.  Comparison of two lots of immune serum globulin for prophylaxis of infectious hepatitis.

Authors:  J W Mosley; D M Reisler; D Brachott; D Roth; J Weiser
Journal:  Am J Epidemiol       Date:  1968-05       Impact factor: 4.897

5.  Immunoglobulin for the prevention of infectious hepatitis in persons working overseas.

Authors:  T M Pollock; D Reid
Journal:  Lancet       Date:  1969-02-08       Impact factor: 79.321

6.  Immunoprophylaxis of viral hepatitis.

Authors:  L B Seeff; J H Hoofnagle
Journal:  Gastroenterology       Date:  1979-07       Impact factor: 22.682

7.  Hepatitis-A-Antibody in commercial lots of immune serum globulin.

Authors:  G G Frŏsner; H Haas; G Hotz
Journal:  Lancet       Date:  1977-02-19       Impact factor: 79.321

8.  Effect of human immune serum globulin on infectivity of hepatitis A virus.

Authors:  S Krugman
Journal:  J Infect Dis       Date:  1976-07       Impact factor: 5.226

9.  Immunoglobulin prophylaxis against hepatitis A among Swedish UN soldiers in an endemic region.

Authors:  O Weiland; J V Berg; E Bäck; P Lundbergh
Journal:  Infection       Date:  1979       Impact factor: 3.553

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  2 in total

1.  Serological hepatitis A virus infections and ratio of clinical to serological infections in a controlled trial of pre-exposure prophylaxis with immune serum globulin.

Authors:  J D Kark; S Bar-Shany; S Shor; L Merlinski; E Nili
Journal:  J Epidemiol Community Health       Date:  1985-06       Impact factor: 3.710

2.  The three-year incidence of non-B viral hepatitis morbidity in a controlled trial of pre-exposure immune serum globulin prophylaxis.

Authors:  J D Kark; E Witztum; H Mazkin; E Nili; Y L Danon
Journal:  Infection       Date:  1984 Jul-Aug       Impact factor: 3.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.